Accelerated approval for cardioprotection would make Bis a revenue generating asset while still progressing through phase 2. Post-approval assets sell for significantly more than phase 2. In the context of the worlds first MOPACS drug, RAC would be the only way of investing into this developing area anywhere in the world.
RAC Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)